Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T. Keyaerts M, et al. Among authors: schallier d. J Nucl Med. 2016 Jan;57(1):27-33. doi: 10.2967/jnumed.115.162024. Epub 2015 Oct 8. J Nucl Med. 2016. PMID: 26449837 Free article. Clinical Trial.
[Targeted therapies in the treatment of non-small cell lung cancer].
De Grève J, Decoster L, Van Meerbeek J, Vermeij J, Teugels E, Schallier D. De Grève J, et al. Among authors: schallier d. Bull Cancer. 2008 Mar;95(3):358-64. doi: 10.1684/bdc.2008.0591. Bull Cancer. 2008. PMID: 18390417 Free article. Review. French.
Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy.
Bral S, Duchateau M, Versmessen H, Verdries D, Engels B, De Ridder M, Tournel K, Collen C, Everaert H, Schallier D, De Greve J, Storme G. Bral S, et al. Among authors: schallier d. Cancer. 2010 Jan 1;116(1):241-50. doi: 10.1002/cncr.24732. Cancer. 2010. PMID: 19918925 Free article. Clinical Trial.
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
De Grève J, Moran T, Graas MP, Galdermans D, Vuylsteke P, Canon JL, Schallier D, Decoster L, Teugels E, Massey D, Chand VK, Vansteenkiste J. De Grève J, et al. Among authors: schallier d. Lung Cancer. 2015 Apr;88(1):63-9. doi: 10.1016/j.lungcan.2015.01.013. Epub 2015 Jan 23. Lung Cancer. 2015. PMID: 25682316 Clinical Trial.
76 results